- Home
- MUFG vs SNY Comparison
MUFG vs SNY Comparison
Compare MUFG & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUFG
- SNY
- Stock Information
- Founded
- MUFG 1880
- SNY 1994
- Country
- MUFG Japan
- SNY France
- Employees
- MUFG N/A
- SNY N/A
- Industry
- MUFG Commercial Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- MUFG Finance
- SNY Health Care
- Exchange
- MUFG Nasdaq
- SNY Nasdaq
- Market Cap
- MUFG 141.2B
- SNY 123.6B
- IPO Year
- MUFG 2001
- SNY N/A
- Fundamental
- Price
- MUFG $12.54
- SNY $49.90
- Analyst Decision
- MUFG
- SNY Buy
- Analyst Count
- MUFG 0
- SNY 2
- Target Price
- MUFG N/A
- SNY $62.50
- AVG Volume (30 Days)
- MUFG 5.7M
- SNY 3.1M
- Earning Date
- MUFG 05-19-2025
- SNY 04-24-2025
- Dividend Yield
- MUFG 3.03%
- SNY 3.21%
- EPS Growth
- MUFG 37.26
- SNY 39.56
- EPS
- MUFG 0.96
- SNY 5.45
- Revenue
- MUFG $39,430,543,625.00
- SNY $48,817,552,946.00
- Revenue This Year
- MUFG $70.59
- SNY $5.35
- Revenue Next Year
- MUFG $0.12
- SNY $6.69
- P/E Ratio
- MUFG $12.69
- SNY $18.73
- Revenue Growth
- MUFG 69.42
- SNY N/A
- 52 Week Low
- MUFG $8.75
- SNY $45.80
- 52 Week High
- MUFG $15.03
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- MUFG 53.09
- SNY 37.47
- Support Level
- MUFG $12.24
- SNY $51.67
- Resistance Level
- MUFG $12.47
- SNY $55.73
- Average True Range (ATR)
- MUFG 0.16
- SNY 0.89
- MACD
- MUFG 0.07
- SNY -0.12
- Stochastic Oscillator
- MUFG 77.55
- SNY 0.34
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.0% share of all domestic loans as of March 2024. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.